Chiesi Global Rare Diseases has entered a co-development agreement with Aliada Therapeutics, a biotechnology company developing a novel blood-brain barrier (BBB)-crossing platform technology to address challenging disease areas with high unmet need.   The collaboration will focus on multiple enzyme cargoes modified with Aliada’s Modular Delivery (MODEL) platform, which harnesses endogenous brain endothelial cell transport mechanisms to efficiently move large molecule therapeutics across ...